Evaluation of asthma–chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease

Journal of Inflammation, Год журнала: 2022, Номер 19(1)

Опубликована: Дек. 6, 2022

Features of asthma and chronic obstructive pulmonary disease (COPD) can coexist in the same patient, a condition termed asthma- overlap (ACO). ACO is heterogeneous exhibiting various combinations COPD features. No clinically acceptable experimental model has been established. We aimed to establish an animal ACO.We generated two phenotypes by administering ovalbumin porcine pancreatic elastase combination, papain. The proinflammatory cytokines cell types bronchoalveolar lavage fluid (BALF) were investigated, lung function parameters measured using FlexiVent system.Greater airway inflammation was observed both models, emphysema found models. proportion eosinophils BALF elevated ACO-a model. Type 2 inflammatory cytokine levels highest model, neutrophil gelatinase-associated lipocalin level Of parameters, compliance greater ACO-b which elastance lower than Airway resistance increased with methacholine concentration but not control or model.We established murine models that exhibit features COPD. validated clinical relevance based on changes profiles function. These will be useful further studies pathogenesis of, therapeutic targets for ACO.

Язык: Английский

---

The Role of Pulmonary Function Testing in the Diagnosis and Management of COPD

Respiratory Care, Год журнала: 2023, Номер 68(7), С. 889 - 913

Опубликована: Июнь 23, 2023

Pulmonary function testing (PFT) has a long and rich history in the definition, diagnosis, management of COPD. For decades, spirometry been regarded as standard for diagnosing COPD; however, numerous studies have shown that COPD symptoms, pathology, associated poor outcomes can occur, despite normal spirometry. Diffusing capacity imaging called into question need to put "O" (obstruction) The role exercise ability PFTs phenotype are reviewed. Although play an important treatment decisions primarily determined by symptom intensity exacerbation history. seminal study positioned FEV

Язык: Английский

---

A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study

World Allergy Organization Journal, Год журнала: 2023, Номер 16(12), С. 100848 - 100848

Опубликована: Дек. 1, 2023

Despite the increasing use of biologics in severe asthma, there is limited research on their asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to ACO and asthma. conducted a multicenter, retrospective, cohort study using data from Precision Medicine Intervention Severe Asthma (PRISM). was defined as post-bronchodilator forced expiratory volume 1 s (FEV1)/forced vital capacity (FVC) <0.7 smoking history >10 pack-years. Physicians selected (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab) based each United States Food & Drug Administration (FDA) approval criteria. After six-month with biologics, both patients (N = 13) asthma 81) showed positive FEV1 (10.69 ± 17.17 vs. 11.25 12.87 %, P 0.652), Control Test score (3.33 5.47 5.39 5.42, 0.290), oral corticosteroid (-117.50 94.38 -115.06 456.85 mg, 0.688), fractional exhaled nitric oxide levels (-18.62 24.68 -14.66 45.35 ppb, 0.415), sputum eosinophils (-3.40 10.60 -14.48 24.01 0.065), blood (-36.47 517.02 -363.22 1294.59, 0.013), exacerbation frequency (-3.07 4.42 -3.19 5.11, 0.943). The odds ratio for time-to-first no significant difference after full adjustments, subgroup analysis according biologic type also similar results. Biologics response patterns were comparable, suggesting that should be actively considered well.

Язык: Английский

---

Innovations in Asthma Care: Efficacy of Mobile App-Assisted Patient Education in Promoting Asthma Self-Management

Опубликована: Янв. 1, 2024

This chapter presents an in-depth analysis of the role mobile apps in enhancing asthma patient education, underscoring their pivotal managing this chronic respiratory condition. Asthma requires consistent monitoring and informed self-management, challenges that are uniquely positioned to address. These offer personalized care plans, enable real-time symptoms medication adherence, foster increased engagement through interactive features. Key functionalities these include symptom tracking, reminders, peak flow recording, access educational content such as inhaler technique videos lifestyle modification advice. The highlights significant impact improving control, ensuring adherence treatment reducing frequency emergency visits. It emphasizes how digital tools empower patients with tailored information, enabling them manage condition proactively, thus quality life. Additionally, addresses limitations health apps, literacy issues, accessibility for diverse populations, need ensure accuracy reliability. underscores importance designing be user-friendly all, including those disabilities or lower literacy, avoid exacerbating healthcare disparities. explores future directions technology, potential integration artificial intelligence machine learning more responsive app experiences. also discusses promising telehealth services, continuity aligning therapeutic strategies. contribute medicine, offering education individual behaviors responses, is highlighted. In conclusion, asserts significantly advance care, shifting paradigm toward a personalized, accessible, effective approach disease management. innovations technology signify move patient-centered model, where individuals empowered knowledge effectively.

Язык: Английский

---

Clinical utilization of airway inflammatory biomarkers in the prediction and monitoring of clinical outcomes in patients with chronic obstructive pulmonary disease

Expert Review of Molecular Diagnostics, Год журнала: 2024, Номер 24(5), С. 409 - 421

Опубликована: Апрель 18, 2024

Chronic obstructive pulmonary disease (COPD) accounts for 545 million people living with chronic respiratory disorders and is the third leading cause of morbidity mortality around world. COPD a progressive disease, characterized by episodes acute worsening symptoms such as cough, dyspnea, sputum production.

Язык: Английский

---

Choosing the right biologic treatment for individual patients with severe asthma – lessons learnt from Picasso.

Respiratory Medicine, Год журнала: 2024, Номер 234, С. 107766 - 107766

Опубликована: Авг. 23, 2024

Severe asthma represents a true challenge for clinicians from two basic perspectives, i.e.: rational assessment of the underlying endo/phenotype and subsequent selection best fitted (personalized) effective treatment. Even though is heterogeneous disease, in majority therapy-compliant patients, it possible to achieve (almost) complete disease control or even remission through conventional quite uniform step-based pharmacotherapy, without phenotyping. However, absence deeper individual patients revealed its handicap fullest extent during first years new millennium upon launch biological therapeutics with most severe forms asthma. The introduction differentially targeted biologics into clinical practice became terms understanding recognizing etiopathogenetic heterogeneity asthmatic inflammation, pheno/endotyping, and, consequently, choose right biologic patient. answers following three questions should lead correct identification dominant pheno/endotype: Is really (severe) asthma? eosinophilic If eosinophilic, (predominantly) allergen-driven? achievable relevant alliance between endotypes phenotypes ("euphenotypes") be based not only on actual characteristics laboratory biomarkers, but more importantly, evaluation their development changes over time. In current paper, we present pragmatic three-step approach diagnosis management.

Язык: Английский

---

Risk Factors for Adults with Chronic Obstructive Pulmonary Disease in the United States, Utilizing State-Based Surveillance

COPD Journal of Chronic Obstructive Pulmonary Disease, Год журнала: 2024, Номер 21(1)

Опубликована: Окт. 11, 2024

Chronic Obstructive Pulmonary Disease (COPD) is a complex and heterogeneous condition. Exposure to tobacco smoke air pollutants are key risk factors for COPD development; however, other include race/ethnicity, sex of adults, history asthma, occupational exposures, chronic respiratory infections. Data the current study were from 2022 Behavioral Risk Factor Surveillance Survey. Chi-squares multinomial logistic regression analyses, adjusted with survey's sampling weight, used examine how critical health indicators impacted diagnosis. Participants (N = 311,175) adults aged 45 years older. Adjusted analyses showed who reported former smoking, poor physical health, depression, less activity, fatigue more likely report COPD. Those be male than female. Moreover, those higher rates insurance coverage, yet had lower income financial difficulty affording doctor services. In follow up analysis, examining racial differences in participants, American Indian odds reporting "other" race groups. Because remains leading cause death disability U.S., disparities persist outcomes, continuing identify vulnerable groups could assist program planners development successful messaging.

Язык: Английский

---

Bronchodilator responsiveness in chronic obstructive pulmonary disease: prevalence, significance, and clinical implications

Current Opinion in Pulmonary Medicine, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 27, 2024

Bronchodilator responsiveness (BDR) is often considered a key feature distinguishing asthma from chronic obstructive pulmonary disease (COPD). However, recent evidence suggests that BDR alone may not be reliable discriminator between these conditions. There still no consensus on definitions and testing protocols. Additionally, it remains unclear whether linked to specific COPD phenotype or influences treatment responses. Our review of literature attempts clarify some issues.

Язык: Английский

---

Clinical Characteristics of T2-Low and T2-High Asthma-Chronic Obstructive Pulmonary Disease Overlap: Findings From COREA Cohort

Allergy Asthma and Immunology Research, Год журнала: 2024, Номер 16(6), С. 601 - 601

Опубликована: Янв. 1, 2024

Despite the emerging biologics, biomarkers and treatment options for asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) are still limited, requiring further research.

Язык: Английский

---

Comparison of Clinical Characteristics and Short-Term Prognoses Within Hospitalized Chronic Obstructive Pulmonary Disease Patients Comorbid With Asthma, Bronchiectasis, and Their Overlaps: Findings From the ACURE Registry

Frontiers in Medicine, Год журнала: 2022, Номер 9

Опубликована: Фев. 25, 2022

Real-world evidence and comparison among commonly seen chronic obstructive pulmonary disease (COPD) phenotypes, i.e., asthma-COPD overlap (ACO), bronchiectasis-COPD (BCO), their coexistence (ABCO) have not been fully depicted, especially in Chinese patients.Data were retrieved from an ongoing nationwide registry hospitalized patients due to acute exacerbation of COPD China (ACURE).Of the eligible 4,813 with COPD, 338 (7.02%), 492 (10.22%), 63 (1.31%) identified as ACO, BCO, ABCO respectively. Relatively, phenotype had a younger age median 62.99 years [interquartile range (IQR): 55.93-69.48] older 70.15 (IQR: 64.37-76.82). The BCO phenotypes similar body mass index 21.79 kg/m2 19.47-23.97) 19.49-24.22), more male gender (79.90%) smokers (71.12%) longer history smoking (median: 32.45 years, IQR: 0.00-43.91). ACO suffered prior allergic episodes proportion 18.05 19.05%, exhibited higher level eosinophil better lung reversibility. Moreover, four showed no significant difference neither all-cause mortality, intensive care unit admission, length hospital stay, Assessment Test score change during hospitalization, nor day 30 outcomes, recurrence exacerbation, all-cause, exacerbation-related readmission.The ABCO, distinct clinical features but varied short-term prognoses. Further validation larger sample is warranted.

Язык: Английский

---